Challenge:

A medium size company with a novel drug in late-stage development for a neurological indication was getting behind on developing a scientific platform and a scientific narrative for the product, due to a). insufficient staffing of the medical team supporting the drug in development; b) lack of internal expertise in the new therapeutic area; and c). the need for customized narratives since both specialists and primary care physicians were expected to prescribe the drug once it is on the market.

Solution:

The first stage of the project involved a quick but thorough exploration of the novel data available on the compound in development, supported by interviews with the development team to understand the Target product profile, its strengths and weaknesses, and areas of differentiation from competition. The second stage comprised a series of interactions with internal medical and commercial experts, to incorporate their learnings, including market research findings.  The third stage, implemented after the Once the draft scientific platform and narratives were generated, a third stage implemented consisting of interviews with a variety of prescribers for validation.  The resulting modular Scientific platform supported scientific narratives for both the specialists and the primary care physicians, successfully meeting the needs of the customers and the company.